Ionis (IONS) price target cut to $85 by Canaccord Genuity
Canaccord Genuity cut its Ionis Pharmaceuticals price target to $85.00 per share from $95.00, while maintaining a Buy rating, according to TradingView News via Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.